Autism-Associated Gene Expression in Peripheral Leucocytes Commonly Observed between Subjects with Autism and Healthy Women Having Autistic Children by Kuwano, Yuki et al.
Autism-Associated Gene Expression in Peripheral
Leucocytes Commonly Observed between Subjects with










1Department of Stress Science, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan, 2Department of Child and Adolescent
Mental Health, National Institute of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan, 3Chichibu-Gakuen Institution and Clinic for Intellectually
Disabled Children, National Rehabilitation Center for Persons with Disabilities, Saitama, Japan
Abstract
Autism spectrum disorder (ASD) is a severe neuropsychiatric disorder which has complex pathobiology with profound
influences of genetic factors in its development. Although the numerous autism susceptible genes were identified, the
etiology of autism is not fully explained. Using DNA microarray, we examined gene expression profiling in peripheral blood
from 21 individuals in each of the four groups; young adults with ASD, age- and gender-matched healthy subjects (ASD
control), healthy mothers having children with ASD (asdMO), and asdMO control. There was no blood relationship between
ASD and asdMO. Comparing the ASD group with control, 19 genes were found to be significantly changed. These genes
were mainly involved in cell morphology, cellular assembly and organization, and nerve system development and function.
In addition, the asdMO group possessed a unique gene expression signature shown as significant alterations of protein
synthesis despite of their nonautistic diagnostic status. Moreover, an ASD-associated gene expression signature was
commonly observed in both individuals with ASD and asdMO. This unique gene expression profiling detected in peripheral
leukocytes from affected subjects with ASD and unaffected mothers having ASD children suggest that a genetic
predisposition to ASD may be detectable even in peripheral cells. Altered expression of several autism candidate genes such
as FMR-1 and MECP2, could be detected in leukocytes. Taken together, these findings suggest that the ASD-associated
genes identified in leukocytes are informative to explore the genetic, epigenetic, and environmental background of ASD
and might become potential tools to assess the crucial factors related to the clinical onset of the disorder.
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Introduction
Autism spectrum disorder (ASD) is a neurodevelopmental
disorder characterized by impairments in reciprocal social
interaction and communication, and restricted and repetitive
behaviors and interests. Several twin studies have consistently
demonstrated a higher concordance for monozygotic than
dizygotic twins [1], [2], [3], [4]. Family studies have shown a
marked increase in the occurrence rate of autism and milder
phenotypes with subtle communication/social impairments or
stereotypic behaviors among the relatives of autistic individuals
compared with those of controls [5], [6]. Considering such
evidence for familial aggregation of autism phenotypes with
various degrees, multiple susceptibility factors, including genetic
factors, are considered to be involved in the clinical manifestation
of autism spectrum, interacting in complex ways with experiential
factors during developmental courses [7].
The susceptibility genes to ASD remain largely unknown yet;
however, recent molecular genomic approaches suggest that
abnormal synaptic homeostasis represents a risk factor for ASD.
For example, ASD-associated genes include glutamate receptors,
gamma-aminobutyric acid (GABA) receptors, neuroligins (NLGNs), neurexin
1, SH3 and multiple ankyrin repeat domains 3 (SHANK3), which are
involved in synapse formation and function [8], [9], [10], [11],
[12]. Several genes that are essential for neurological development,
such as roundabout, axon guidance receptor, homolog 1 (ROBO1) and early
growth response 2 (EGR2) are also differentially expressed in the
lympnoblastoid cell lines from monozygotic twins discordant in
severity of autism spectrum [13]. Neuronal differentiation- and
survival-associated genes, such as wingless-type MMTV integration site
family member 2 (WNT2) and homeobox A1 (HOXA1) were also
reported as autism susceptibility genes [14], [15]. A large-scale
single nucleotide polymorphism (SNP) association analysis involv-
ing 1,168 multiplex families revealed a single region on
chromosome 11p12-p13 that exceeded the threshold for suggestive
linkage as autism risk loci [16]. Recently, analysis in human
postmortem cortical tissues from ASD cases has shown the
association between a SNP in the promoter of the met proto-oncogene
(MET) gene and a risk for ASD [17], [18]. This gene encodes the
MET receptor tyrosine kinase and contributes to development of
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sticthe cerebral cortex and cerebellum, which process may be
disrupted in autism. Voineagu et. al. have reported that analysis
of postmortem brain tissue samples from autism cases showed the
splicing dysregulation and altered gene expression involved in
neuronal and synaptic signaling dysfunction in the ASD brain
[19].
Multiple susceptible factors are likely to influence directly or
indirectly gene expression, resulting in functional alterations in
proteins regulating synaptic homeostasis. The altered gene expression
could be detected as gene expression signatures unique to ASD even
in peripheral tissues. Increasing molecular genomic studies have
indicated the importance of differential expression of ASD-associated
genes in peripheral tissues as well as postmortem brains from subjects
with ASD [13], [20], [21]. For example, gene expression profiling of
lymphoblastoid cell lines are well-studied because of their character-
istically homogeneity. These findings led us to speculate that ASD-
associated changes in gene expression could be detectable in
peripheral blood leucocytes from individuals with ASD.
In addition, identification of genetic etiology of ASD is
hampered by the heterogeneity of autism phenotypes. One way
of explaining this heterogeneity is broadening studies beyond the
strict diagnosis of autism, by doing this, it may determine which
components of the autistic symptoms are genetically transmitted
and how these components interact [7]. To prove this hypothesis,
we examined gene expression in peripheral blood from subjects
with ASD and healthy mothers having children with ASD, and
found an ASD-associated gene expression signature commonly
observed in both individuals with ASD and healthy mothers
having children with ASD, between whom there was no blood
relationship. These findings may provide novel information for
understanding the genetic background of ASD.
Methods
Study Subjects
The present study was approved by the Ethics Committee of the
National Center of Neurology and Psychiatry (NCNP), Japan and
by the Human Study Committee of the Tokushima University
Hospital, Japan. After the experimental procedures were fully
explained, written informed consent was obtained from each
parent of minor subject and participants himself/herself, or from
each adult subject. Adolescents and adults with ASD (17 males and
4 females; aged 26.765.5 y (mean6SD), range 18–38 y, n=21)
and the healthy women who had children with ASD (asdMO;
44.766.7 y, range 33–58 y, n=21) were recruited from our
research volunteer pool or specialized clinics and enrolled as the
ASD group and the asdMO group, respectively. Subjects of the
ASD group and those of asdMO group were biologically unrelated
each other. The pre-existing clinical diagnoses of ASD were
confirmed according to the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV-TR, American Psychiatric Associa-
tion, 2000) based on clinical interviews with subjects and/or
parents using semi-structured interviews that were validated for
Japanese pervasive developmental disorders (PDD) populations
[22] by our research team including experienced child psychiatrist
and developmental pediatrician. To corroborate the ASD
diagnosis, the Japanese version of the Autism Spectrum Quotient
(AQ-J) [23], [24] were completed by themselves and those scores
except 3 subjects were above the cut-off of 26 (Table 1).
Intellectual functions of the ASD subjects were evaluated using
Japanese versions of WAIS-III: all ASD subjects exhibited normal
IQ (mean full scale IQ; 91.86621.62) (Table 1).
Additionally, age- and sex-matched healthy volunteers were
recruited from students or staffs of the Faculty of Medicine, the
University of Tokushima and NCNP, and the local communities,
and enrolled as controls for the ASD group (Control group; aged
27.065.5 y, range 19–39 y, n=21) or controls for asdMO group
(ctrlMO group; aged 44.766.7 y, range 31–59 y, n=21). We
confirmed that they did not have any serious physical or mental
disorders including ASD in the past and at present, the children of
the ctrlMO group have not been diagnosed as ASD and were in
good health by interviews. All control subjects had not been
medicated at least for three months prior to the recruitment.
RNA preparation, amplification, and hybridization
Venous blood (5 ml) was taken from each subject and
immediately poured into PAXgene
TM blood RNA tubes (Qiagen,
Hilden, Germany). Total RNA was purified using a PAXgene
Blood RNA kit (Qiagen) according to the manufacture’s protocol.
Contaminated DNA was removed using a DNase kit (Qiagen). The
quality of the purified RNA and its applicability for microarray
analysis wereassessed by the Agilent 2100 Bioanalyzer using a RNA
6000 Nano Labchip kit (Agilent Technologies, Palo Alto, CA,
USA). High quality RNA with a RIN number above 8.0 was used
for microarray analysis and quantitative real-time reverse transcrip-
tion-PCR (qPCR). For microarray analysis, total RNA (400 ng) was
used for amplification and labeling of complementary RNA (cRNA)
using a Low RNA Input Linear Amplification Kit PLUS and a
succinimide-containing fluorescent dye (Cy3)-CTP according to the
manufacturer’s protocol (Agilent). Cy3-labeled cRNA was applied
to the whole human genome oligoDNA microarray (4644 k;
Agilent) following the manufacturer’s protocol. Hybridization was
performed at 65uC for 17 h. After washing, fluorescence intensity at
each spot was measured using a G2565BA Microarray Scanner
(Agilent). Table S1 summarizes the array design and profile of
subjects that were analyzed in this study.
Microarray analysis
Signal intensities of Cy3 were quantified and analyzed by
subtracting backgrounds using Feature Extraction 10 software
(Agilent). Raw data output was imported into Genespring GX10
(Agilent) and normalized each chip to the 75th percentile of all
measurements (per chip normalization), and normalized each
probe to the median expression of matched control intensity for
that gene across all samples (per gene normalization). Following
normalization, we filtered genes having fluorescence intensities
higher than a cutoff value of 50 among all samples.
Pathway and functional analyses
The data sets of differentially expressed genes between the ASD
and Control group, and the asdMO and ctrlMO group were
analyzed using Ingenuity Pathway Analysis (IPA) application
(Ingenuity Systems, Mountain View, CA, USA). IPA was used to
identify molecular and cellular processes, biological functions, and
modules of functionally related genes modified by the genes
identified as significantly differentially expressed. IPA utilizes the
knowledge in the literature about biological interactions among
genes and proteins. The probability of a relationship between each
biological function and the identified genes was calculated by
Fisher’s exact tests. The level of significance was set at p-value of
0.05. A detailed description is given in the online repository
(http://www.ingenuity.com).
Quantitative real-time reverse transcription PCR (qPCR)
analysis
qPCR was done to validate the results obtained by the
oligoDNA microarray. Total RNA (400 ng) from each sample
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ID gender age AQ score WAIS
ASD (n=21) SUM VIQ PIQ FIQ
1 M 18 34 126 109 122
2 M 18 30 91 92 91
3 M 20 . 67 82 71
4 M 20 32 88 61 72
5 M 22 31 70 54 60
6 M 23 . 59 62 54
7 M 24 30 109 95 104
8 M 24 31 106 91 100
9 M 26 36 88 70 78
10 M 26 30 72 75 71
11 M 27 31 103 84 94
12 M 28 28 98 64 82
13 M 29 . 77 83 78
14 M 29 32 114 128 121
15 M 32 24 132 115 127
16 M 34 21 108 106 107
17 M 38 29 92 64 78
18 F 27 19 111 102 108
19 F 28 37 85 78 80
20 F 32 30 119 110 117
21 F 35 39 105 112 114
mean6SD 26.6765.53 y 30.2265.06 96.19619.92 87.48621.62 91.86621.62
asdMO (n=21)
1F 3 3. . . .
2F 3 6. . . .
3F 3 7. . . .
4F 3 9. . . .
5F 3 9. . . .
6F 4 1. . . .
7F 4 1. . . .
8F 4 1. . . .
9F 4 2. . . .
10 F 44 . . . .
11 F 46 . . . .
12 F 46 . . . .
13 F 47 . . . .
14 F 47 . . . .
15 F 49 . . . .
16 F 49 . . . .
17 F 50 . . . .
18 F 51 . . . .
19 F 51 . . . .
20 F 58 . . . .
21 F 58 . . . .
mean6SD 44.7366.66 y
IQ=Intelligence Quotients; VIQ=Verbal IQ; PIQ=Performance IQ; FIQ=Full IQ; AQ=Autism-Spectrum Quotient; M=Male; F=Female; y=year.
doi:10.1371/journal.pone.0024723.t001
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TM
III (invitrogen, Carlsbad, CA, USA). PCR reaction was performed
with synthesized cDNA using the ABI-PRISM 7500 sequence
detection system and TaqMan Gene Expression Master Mix
(Applied Biosystems) according to the manufacture’s protocols.
For measurement of quantitative gene expression levels, we
purchased oligonucleotide primers and gene-specific TaqMan
probes from Applied Biosystems (Table S2). Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and histone deacetylase 1(HDAC1)
were used as endogenous quantity controls. Data were analyzed
using SDS 2.3 software (Applied Biosystems). Quantity values were
normalized by GAPDH or HDAC1 mRNA levels. After the relative
ratios of each mRNA expression level between the ASD and
Control group, and the asdMO and ctrlMO group were
calculated, the unpaired t tests were used to compare the relative
ratios for each mRNA for two pairs.
Results
Altered gene expression in peripheral blood in the ASD
group
First, we examined differentially expressed genes in peripheral
leukocytes between 21 subjects with ASD and their age- and
gender-matched healthy controls. Microarray measurement
showed that 19,194 probes in total had fluorescence intensities
higher than a cut-off value of 50 among all samples. Unpaired t test
with Benjamini-Hochberg correction for multiple comparisons at
the 0.05 false discovery rate (FDR) selected 9,784 probes that were
differentially expressed between the ASD and Control groups. The
raw and normalized values for all samples by microarray analysis
were deposited in the Gene Expression Omnibus (GEO) database
(accession number: GSE26415). When the fold-change criterion
was set at . 2-fold in the mean expression level, 28 probes passed
the criterion and corresponded to 19 annotated genes. Among
them, 18 genes (NOVA2, SLC22A18AS, C21orf58, LZTR2, RKHD1,
BC018095, FAM124A, LHB, TAOK2, UBL4A, ITGA2B, PLCXD2,
NRN1, KLHDC7A, MYOG, NUMBL, WDTC2,a n dSDK2) were
significantly up-regulated, while one gene (UTS2) was down-
regulated in the ASD group. These transcripts are listed according
to greatest fold change in expression in Table 2.
The 19 differentially expressed genes were then subjected to the
biofunctional pathway analysis using IPA. The net work analysis
ranked ‘‘cell morphology, cellular assembly and organization, nerve
system development and function’’ as the top-scoring net work
(Figure 1). Particularly, 12 (C21ORF58, ITGA2B, LHB, MYOG,
N O V A 2 ,N R N 1 ,N U M B L ,P L C X D 2 ,S D K 2 ,T A O K 2 ,U T S 2and
WDTC1) out of the 19 genes were included in this network. The
molecules encoded by 11 up- or 1 down-regulated genes are shown in
red and green in this network, respectively (Figure 1). The network
analysis picked up several other networks, but only one or two genes
were included in those networks. The top-scored biofunctions
modified by the 19 genes significantly (p,0.05 by Fisher’s exact test)
were 1) cardiovascular disease (p-value: 3.46E-04), 2) vitamin and
mineral metabolism(7.08E-04),3) cell signaling (7.08E-04),4) cellular
development(9.90E-04),and5)geneticdisorder(9.90E-04).Although
we examined the probability of a relationship between the identified
19 genes and each canonical pathway, IPA did not show any
significantly modified pathway with p value of ,0.01.
Differentially expressed genes in the asdMO group
Using a similar way to that mentioned above for the ASD
group, 57 annotated genes from 176 probes were identified to be
Table 2. Differentially expressed genes for the ASD group compared with the Control group.
Accession No. GeneSymbol Description fold change corrected p-value
Up-regulated gene
NM_002516 NOVA2 neuro-oncological ventral antigen 2 2.34 8.23E-03
NM_007105 SLC22A18AS solute carrier family 22 (organic cation transporter), member 18 antisense 2.29 4.06E-03
NM_199071 C21ORF58 chromosome 21 open reading frame 58 2.25 4.19E-03
BC009106 LZTR2 (SEC16B) leucine zipper transcription regulator 2 2.22 7.49E-03
NM_203304 RKHD1 (MEX3D) ring finger and KH domain containing 1 2.22 4.27E-03
BC018095 BC018095 hypothetical protein LOC441869 2.21 6.92E-03
NM_145019 FAM124A family with sequence similarity 124A 2.14 4.07E-03
NM_000894 LHB luteinizing hormone beta polypeptide 2.13 1.09E-02
NM_016151 TAOK2 TAO kinase 2 2.13 1.03E-02
NM_014235 UBL4A ubiquitin-like 4A 2.12 9.31E-03
NM_000419 ITGA2B integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) 2.12 4.90E-04
NM_153268 PLCXD2 phosphatidylinositol-specific phospholipase C, X domain containing 2 2.12 7.29E-03
NM_016588 NRN1 neuritin 1 2.10 4.90E-03
NM_152375 KLHDC7A kelch domain containing 7A 2.08 1.37E-02
NM_002479 MYOG myogenin (myogenic factor 4) 2.07 1.06E-02
NM_004756 NUMBL numb homolog (Drosophila)-like 2.03 1.19E-02
NM_015023 WDTC1 WD and tetratricopeptide repeats 1 2.03 1.27E-02
NM_019064 SDK2 Homo sapiens sidekick homolog 2 (chicken) 2.01 4.70E-03
Down-regulated gene
NM_021995 UTS2 urotensin 2 24.25 1.67E-03
*corrected p-value was calculated by unpaired t test with Benjamini-Hochberg correction for multiple comparisons at the 0.05 false discovery rate (FDR).
doi:10.1371/journal.pone.0024723.t002
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ctrlMO group (Table 3). The 57 genes were composed of 17 up-
regulated and 40 down-regulated genes in the asdMO group.
Analysis of the 57 genes with IPA indicated that ‘‘cancer, RNA
post-transcriptional modification and reproductive system disease’’
was ranked as the top network in which 14 down-regulated genes
were involved (Figure 2). The 57 genes significantly changed 57
biofunctional pathways in total. The most remarkable change was
observed in the function of protein synthesis (p-value=2.48E-08).
Particularly, 10 genes encoding ribosomal proteins (RPL7, RPL26,
RPL31, RPL34, RPL39, RPL41, RPL9, RPS17, RPS27L, and
RPS3A) were significantly down-regulated in the asdMO group.
Furthermore, several down-regulated (CD69, TNFRSF17, and
BCL2A1) and up-regulated (KRT1 and C4B) were involved in
several immune functions, such as antigen presentation (p-
value=1.95E-07), cell-mediated immune response (p-va-
lue=1.49E-05), and humoral immune response (p-value=1.49E-
05). As for the canonical pathway analysis, IPA did not reveal any
significantly pathway modified by the 57 genes.
Similarity in gene expression profiling between the ASD
and asdMO group
As described above, we identified 19 differentially expressed
genes in young subjects with ASD compared their age- and sex-
matched controls, and 57 differentially expressed genes comparing
healthy women with and without ASD children. Among the 19
and 57 genes which were separately identified according to our 2-
fold change criterion by two comparisons, three genes (ITGA2B,
LHB, and LZTR2) overlapped (Figure 3A). It should be noted that
expression of the 19 genes (Figure 3B) and the 57 genes (Figure 3C)
changed in a parallel direction between the ASD and asdMO
group, indicating that healthy women having ASD children shared
some gene expression signature in common with individuals
diagnosed as ASD, although they had no full symptoms above
clinical threshold of ASD. When the fold change criterion was
lowered from . 2.0 to . 1.5, 496 differentially expressed genes
were identified in the ASD group compared with the Control
group. In this case, 399 out of 496 genes were also included in
1126 genes differentially expressed in the asdMO group compared
with the ctrlMO group by a looser cutoff of 1.5-fold change
(Figure 3D), and the altered direction of 399 genes was similar
between the ASD and asdMO group (Figure 3E). The 399
overlapping genes are listed in Table S3. We also examined a
pathway or functional analysis of the 399 genes. As shown in
Table 4, the network analysis ranked ‘‘Nervous System Develop-
ment and Function, Tissue Development, Genetic Disorder’’ as
the top-scoring net work. Subsequently, the overlapping gene set
modified ‘‘Cell-To-Cell Signaling and Interaction, Tissue Devel-
opment, Embryonic Development’’ and ‘‘Gene Expression,
Cellular Growth and Proliferation, Hematological System Devel-
opment and Function’’. The top-scored biofunctions modified by
the overlapping genes were 1) Cell-To-Cell Signaling and
Figure 1. Ingenuity pathway analysis of differentially expressed genes for the ASD group compared with the Control group. The top
scored network using the 19 differentially expressed genes for the ASD group (. 2-fold vs. control) is ‘‘cell morphology, cellular assembly and
organization, nerve system development and function’’, with 12 focus molecules and a score of 31. The network is displayed graphically as nodes
(gene) and edges (the biological relationship between genes). The color intensity indicates the genes up-regulated or down-regulated in ASD are
shown in red or green, respectively. The mean of log2 expression values compared with the Control group are described as logarithm scale.
doi:10.1371/journal.pone.0024723.g001
Autism-Associated Gene Expression Signatures
PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e24723Table 3. Differentially expressed genes for the asdMO group compared with the ctrlMO group.
Accession No. GeneSymbol Description fold change corrected p-value
Up-regulated gene
AK024445 C14ORF56 chromosome 14 open reading frame 56 2.85 1.16E-03
NM_020478 ANK1 ankyrin 1, erythrocytic 2.73 1.32E-03
NM_015431 TRIM58 tripartite motif-containing 58 2.66 3.81E-03
NM_138368 DKFZP761E198 DKFZp761E198 protein 2.54 2.40E-03
BC009106 LZTR2 (SEC16B) SEC16 homolog B (S. cerevisiae) 2.33 4.54E-02
NM_000419 ITGA2B integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen
CD41)
2.29 6.45E-03
NM_001266 CES1 carboxylesterase 1 (monocyte/macrophage serine esterase 1) 2.23 5.81E-03
NM_001002029 C4B complement component 4B (Chido blood group) 2.21 2.46E-02
NM_001001957 OR2W3 olfactory receptor, family 2, subfamily W, member 3 2.15 1.50E-02
NM_000894 LHB luteinizing hormone beta polypeptide 2.15 4.37E-02
NM_006121 KRT1 keratin 1 2.13 1.67E-02
NM_002501 NFIX nuclear factor I/X (CCAAT-binding transcription factor) 2.09 3.31E-03
NM_001039476 NPRL3 (C16ORF35) nitrogen permease regulator-like 3 (S. cerevisiae) 2.06 4.84E-03
NM_006798 UGT2A1 UDP glucuronosyltransferase 2 family, polypeptide A1 2.06 2.74E-02
NM_001024858 SPTB spectrin, beta, erythrocytic 2.05 4.05E-03
NM_198149 SHISA4 shisa homolog 4 (Xenopus laevis) 2.02 1.20E-02
NM_007371 BRD3 bromodomain containing 3 2.02 1.11E-03
Down-regulated gene
NM_002624 PFDN5 prefoldin subunit 5 22.00 7.37E-03
NM_012459 TIMM8B translocase of inner mitochondrial membrane 8 homolog B (yeast) 22.01 8.93E-04
NM_014463 LSM3 LSM3 homolog, U6 small nuclear RNA associated (S. cerevisiae) 22.01 1.59E-03
AB075859 ZNF525 zinc finger protein 525 22.01 2.31E-03
NM_002489 NDUFA4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 9kDa 22.02 2.77E-03
NM_001803 CD52 CD52 molecule 22.03 2.58E-03
NM_001019 RPS15A ribosomal protein S15a 22.03 3.73E-03
NM_005034 POLR2K polymerase (RNA) II (DNA directed) polypeptide K, 7.0kDa 22.05 2.56E-03
NM_001021 RPS17 ribosomal protein S17 22.06 4.70E-03
NM_021104 RPL41 ribosomal protein L41 22.09 6.64E-03
NM_001781 CD69 CD69 molecule 22.09 4.54E-03
NM_005340 HINT1 histidine triad nucleotide binding protein 1 22.12 1.96E-03
NM_000971 RPL7 ribosomal protein L7 22.12 4.29E-03
NM_007333 KLRC3 killer cell lectin-like receptor subfamily C, member 3 22.12 6.86E-03
NM_016304 RSL24D1 (C15orf15) ribosomal L24 domain containing 1 22.12 5.56E-03
NM_203495 COMMD6 COMM domain containing 6 22.15 5.13E-03
NM_015920 RPS27L ribosomal protein S27-like 22.17 2.01E-03
NM_019051 MRPL50 mitochondrial ribosomal protein L50 22.18 1.16E-03
NM_001026 RPS24 ribosomal protein S24 22.18 2.80E-03
NM_002370 MAGOH mago-nashi homolog, proliferation-associated (Drosophila) 22.19 5.86E-04
NM_001192 TNFRSF17 tumor necrosis factor receptor superfamily, member 17 22.23 1.83E-02
NM_005213 CSTA cystatin A (stefin A) 22.23 1.70E-03
NM_002586 PBX2 pre-B-cell leukemia homeobox 2 22.27 3.17E-03
NM_000987 RPL26 ribosomal protein L26 22.27 6.54E-03
NM_003096 SNRPG small nuclear ribonucleoprotein polypeptide G 22.30 2.26E-03
NM_004049 BCL2A1 BCL2-related protein A1 22.32 4.72E-03
NM_001000 RPL39 ribosomal protein L39 22.34 2.94E-03
NM_006294 UQCRB ubiquinol-cytochrome c reductase binding protein 22.34 2.79E-03
NM_000985 RPL17 ribosomal protein L17 22.37 1.61E-03
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NM_016093 RPL26L1 ribosomal protein L26-like 1 22.37 2.28E-03
NM_015235 CSTF2T cleavage stimulation factor, 39 pre-RNA, subunit 2, 64kDa, tau variant 22.41 1.80E-03
NM_000661 RPL9 ribosomal protein L9 22.47 1.82E-03
NM_004280 EEF1E1 eukaryotic translation elongation factor 1 epsilon 1 22.49 8.51E-04
NM_005127 CLEC2B C-type lectin domain family 2, member B 22.53 1.45E-03
NM_000993 RPL31 ribosomal protein L31 22.57 3.59E-03
NM_006713 SUB1 SUB1 homolog (S. cerevisiae) 22.59 2.15E-03
NM_001011 RPS7 ribosomal protein S7 22.59 1.70E-03
NM_033625 RPL34 ribosomal protein L34 22.64 3.73E-03
BC049823 RPL22L1 ribosomal protein L22-like 1 22.84 1.16E-03
NM_001006 RPS3A ribosomal protein S3A 23.08 1.64E-03
*corrected p-value was calculated by unpaired t test with Benjamini-Hochberg correction for multiple comparisons at the 0.05 FDR.
doi:10.1371/journal.pone.0024723.t003
Table 3. Cont.
Figure 2. Ingenuity pathway analysis of differentially expressed genes for the asdMO group compared with the ctrlMO group. The
top scored network using the 57 genes identified as differentially expressed genes for the asdMO group (. 2-fold vs. ctrlMO) is ‘‘cancer, RNA post-
transcriptional modification, reproductive system disease’’, with 14 focus molecules and a score of 27. The color intensity indicates the genes up-
regulated or down-regulated in asdMO are shown in red or green, respectively. The mean of log2 expression values compared with the ctrlMO group
are described as logarithm scale.
doi:10.1371/journal.pone.0024723.g002
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ment and Function (5.86E-06), 3) Tissue Development (5.86E-06).
These results indicated that some genetic predisposition of ASD
specifically found in the ASD group was also shared by only
healthy women having ASD children, but not healthy women
having non-ASD children or healthy adults, which could be
detectable as an ASD-associated gene expression signature in
peripheral leukocytes.
Confirmation by qPCR
Based on the microarray data, we selected putative ASD-
associated genes (16 out of the 19 ASD-associated genes identified
by comparison between the ASD and Control group, and 19 out
of 57 asdMO-associated genes by comparison between the asdMO
and ctrlMO group, shown in Table 5) and validated changes in
their expression levels using qPCR. Among the 19 ASD-associated
genes, three mRNA levels (C21orf58, SDK2, and BC018095) could
not be measured, since appropriate TaqMan gene probes for them
were not available. Among the 57 asdMO-associated genes, we
preferentially selected a group of genes encoding key molecules in
the regulation of the top-scoring biological function (protein
synthesis). GAPDH mRNA levels were used as an internal control.
In addition, we measured HDAC1 mRNA levels as another
internal quantity control, since the microarray measurement
showed constant expression levels of these two mRNAs among all
subjects, which were also confirmed by qPCR. The result using
Figure 3. Similarity in gene expression profiling between the ASD and asdMO group. Venn diagram of differentially expressed genes for
the ASD group compared with the Control group and the asdMO group compared with the ctrlMO group (. 2-fold change) (A). RNA was prepared
from each group and subjected to microarray analysis. Differentially expressed 19 and 57 genes by .2-fold in ASD group and asdMO group,
respectively. Three genes were overlapped. The mean of expression values of the 19 genes (B) and the 57 genes (C) changed in a parallel direction
between the ASD and asdMO group. The normalized intensity value of genes, which was up-regulated or down-regulated by 2-fold, is shown in red
or green, respectively, compared with control or ctrlMO. Venn diagram of differentially expressed 496 and 1126 genes by .1.5-fold in ASD group and
asdMO group (D). 399 genes were overlapped. The mean of expression values of the overlapped 399 genes was similar direction between the ASD
and asdMO group (E). The normalized intensity value of genes, which was up-regulated or down-regulated by 1.5-fold, is shown in red or green,
compared with control.
doi:10.1371/journal.pone.0024723.g003
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instead (data not shown).
Of the 16 ASD-associated genes, we could confirm significant
changes in mRNA levels in only four genes (ITGA2B, NRN1,
WDTC1, and PLCXD2). ITGA2B and NRN1 were also detected as
significantly up-regulated in the asdMO group (Table 5). Changes
in the other mRNA levels were not significant.
Of the measured 19 asdMO-associated genes, 14 genes (CSTA,
CLEC2B, RPL34, EEFE1, RPL9, RPS3A, CES1, ANK1, BCL2A1,
RPS7, SUB1, TRIM58, RPL39, and SPTB) were validated to
significantly alter their mRNA levels. All genes except BCL2A1
also significantly changed their expression in the same direction in
the ASD group (Table 5).
In addition to the 35 genes described above, we measured
mRNA levels of six genes known as putative ASD-related genes
based on the previous studies; FMR1, MET, MECP2, NRXN1,
UBE3A, and SLC9A6 [25]. All these genes were not included in the
19 ASD-associated genes when identified using the 2-fold
criterion, but MECP2, NRXN1, UBE3A, and SLC9A6 were
included in the 496 ASD-associated genes, when the fold-change
criterion was set at .1.5-fold. As shown in Table 5, MECP2
mRNA levels were found to elevate significantly in both the ASD
and asdMO groups by qPCR, and FMR1 expression significantly
reduced only in the ASD group, compared with the respective
controls.
Discussion
Using a whole human genome microarray and the statistical
analysis with 2-fold change criteria, we first identified the 19 genes
differentially expressed in peripheral leukocytes between subjects
with ASD and their age- and sex-matched controls. These ASD-
associated genes were preferentially included in the network of cell
morphology, cellular assembly and organization, nerve system
development and function. In addition, we identified the 57 genes
whose mRNA levels were significantly different between unaffect-
ed mothers having children with ASD and mothers having
children without any mental disorders. Differential expression of
the 57 genes could be characterized as significant alterations of
biosynthesis of protein and processing of ribosomal RNA.
Intriguingly, unaffected mothers having children diagnosed with
ASD possessed a unique gene expression signature, which could
also be detected in the affected subjects with ASD, although the
mothers having affected children and affected subjects had no
direct heredity of blood between them.
Based on the twin and family studies, the etiology of autism has
a substantial genetic component [25]. With genome-wide
differential display approaches, a number of recent studies have
highlighted SNPs, copy number variants (CNVs), and epigenetic
factors in the dysregulated expression of candidate genes related to
the occurrence of autism [26]. Putative and known candidates for
susceptibility to autism are categorized to differentiation of
neurons (e.g. DISC1, MET, PTEN, and ITGB3), neuronal cell
adhesion (e.g. NRXN1, NLGN3, and NLGN4X), transmission of
nervous system (e.g. OXTR, SLC6A4, GABRB3, and SHANK3), and
regulation of neuronal activity (e.g. FMR1, MECP2, and UBE3A).
In addition to the known ASD-related genes (FMR1, MET,
MECP2, NRXN1, UBE3A, and SLC9A6), we selected 36 genes from
the 19 and 57 genes, and then validated changes in mRNA levels
of 42 genes in total by qPCR. Finally, we found that expression of
the 15 genes (ITGA2B, NRN1, CSTA, CLEC2B, RPL34, EEFE1,
RPL9, RPS3A, CES1, ANK1, RPS7, SUB1, TRIM58, RPL39, and
SPTB) was significantly changed to the same direction in both
ASD subjects and women having ASD children (Table 5).
We observed that mRNA levels of ITGA2B encoding glycopro-
tein (GP) aIIb were up-regulated about 2-fold in the peripheral
leukocytes of the both ASD and asdMO groups (Table 5). GP aIIb
forms aIIbb3 integrin with GP bIII encoded by ITGB3 [27]. ITGB3
is known as an autism-susceptible gene, which was identified as a
male quantitative trait locus for whole blood serotonin levels [28].
aIIbb3 integrin has an important role in the cell morphology,
including synapse maturation. The increased expression of ITGA2B
mRNA might modify cellular morphology of peripheral cells in
mothers having children with ASD as well as subjects with ASD.
Another interesting observation was the reduction of SUB1
mRNA expression in ASD and asdMO groups. SUB1 encodes a
transcription factor that activates RNA polymerase II transcrip-
tion. A recent study has shown that SUB1 is also involved in the
transcription of the MET receptor tyrosine kinase [29]. The
significant down-regulation of SUB1 observed in our ASD subjects
may be related to the reduction of MET protein reported in ASD
cases [17], [18].
In addition to the important findings described above,
validation of candidate genes by qPCR provided novel and
unique gene expression changes in subjects with ASD and healthy
women having ASD children. Interestingly, several genes
Table 4. Biological roles of overlapping genes (.1.5-fold change) between ASD and asdMO group.
A) Associated Network Functions for overlapping genes
score
Nervous System Development and Function, Tissue Development, Genetic Disorder 40
Cell-To-Cell Signaling and Interaction, Tissue Development, Embryonic Development 36
Gene Expression, Cellular Growth and Proliferation, Hematological System Development and Function 34
B) Top Biofunctions for overlapping genes
P-value range No. of molecules
Cell-To-Cell Signaling and Interaction 5.86E-06 - 2.41E-02 44
Reproductive System Development and Function 5.86E-06 - 2.19E-02 19
Tissue Development 5.86E-06 - 2.69E-02 30
Hematological Disease 1.04E-05 - 2.46E-02 24
Gastrointestinal Disease 4.65E-05 - 2.45E-02 13
doi:10.1371/journal.pone.0024723.t004
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Control ASD ctrlMO asdMO p-value
Gene relative expression expression value expression value expression value
mean±SEM mean±SEM mean±SEM mean±SEM ASD vs control asdMO vs ctrlMO
(ASD-related)
ITGA2B 4.6860.92 8.4760.94 5.6262.35 9.6461.93 4.0E-03* 5.11E-03*
NRN1 3.5360.40 5.4160.59 3.9260.58 6.6560.85 2.2E-02* 4.08E-02*
WDTC1 1.2360.09 1.5760.11 1.2760.10 1.6060.16 2.5E-02* 3.50E-01
PLCXD2 1.0960.11 0.7360.06 0.9360.09 0.7960.11 6.2E-03* 6.01E-02
UTS2 1.2460.31 1.0060.30 0.9860.21 0.6160.16 8.1E-02 4.55E-01
KLHDC7A 1.1760.17 0.8060.10 1.0060.20 0.7860.23 6.0E-01 4.89E-01
LHB 2.0360.21 1.7460.19 2.2160.37 1.8160.24 3.5E-01 3.82E-01
LZTR2 0.6860.68 0.5560.54 1.0361.03 0.7660.76 6.3E-01 5.88E-01
NUMBL 0.7260.07 0.9060.14 1.1760.21 1.1760.29 8.1E-01 7.39E-01
RKHD1 1.0260.14 0.8460.14 1.3660.18 1.1060.21 2.6E-01 1.38E-01
SLC22A18AS 4.5360.49 4.6560.46 3.7960.40 5.3260.84 6.9E-01 3.67E-01
TAOK2 0.6260.06 0.7860.11 0.9360.14 0.8760.19 2.1E-01 3.84E-01
UBL4A 1.0660.06 1.1560.08 1.0460.05 1.0260.11 3.6E-01 4.46E-01
NOVA2 u.d. u.d. u.d. u.d.
FAM124A u.d. u.d. u.d. u.d.
MYOG u.d. u.d. u.d. u.d.
(asdMO-related)
CSTA 0.5560.06 0.4060.05 0.8160.11 0.3960.07 2.9E-02* 3.45E-04*
CLEC2B 0.8860.06 0.6860.12 1.5060.14 0.8860.13 1.5E-02* 7.50E-04*
RPL34 0.7160.06 0.5160.10 1.0760.13 0.6360.12 8.8E-03* 2.04E-03*
EEF1E1 0.4960.05 0.3460.06 0.5860.05 0.3860.07 5.5E-03* 4.39E-03*
RPL9 0.5060.07 0.3460.08 0.6860.09 0.4260.12 1.0E-02* 4.85E-03*
RPS3A 0.5160.05 0.3560.06 0.6460.07 0.4060.09 3.7E-03* 3.31E-03*
CES1 2.5660.41 10.0964.63 2.6060.48 5.5660.89 5.4E-03* 6.88E-03*
ANK1 7.9861.32 12.2361.44 7.8061.37 18.2962.87 2.3E-02* 5.88E-03*
BCL2A1 0.6960.10 0.5160.10 1.2860.30 0.6560.12 1.1E-01 1.26E-02*
RPS7 0.5660.07 0.2960.06 0.7460.14 0.3760.07 2.5E-03* 7.73E-03*
SUB1 0.3260.04 0.2160.04 0.3660.04 0.2860.07 4.9E-03* 3.06E-02*
TRIM58 5.9260.77 9.7161.11 6.4261.37 12.4162.36 1.4E-02* 2.51E-02*
RPL39 0.7260.17 0.3860.09 0.7760.13 0.5260.14 2.4E-02* 3.18E-02*
SPTB 2.9360.45 4.8960.66 3.3260.78 8.0261.78 2.2E-02* 2.98E-02*
UQCRB 0.4960.05 0.4160.05 0.5160.05 0.3960.03 1.5E-01 1.98E-01
PBX2 0.9260.09 0.9460.12 0.7460.14 1.1460.23 8.4E-01 6.46E-02
SNRPG 0.5560.06 0.4060.06 0.5360.07 0.4260.06 1.8E-02* 2.75E-01
NDUFA4 2.8160.37 2.8960.38 2.6860.36 3.3660.39 7.4E-01 9.06E-02
(putativeASD-related)
FMR1 1.0560.06 0.7160.07 1.0060.12 0.9260.10 3.8E-03* 7.13E-01
MECP2 1.0160.04 1.2260.08 0.9960.05 1.3360.09 4.5E-02* 3.47E-03*
SLC9A6 1.7460.15 1.3760.13 1.5360.15 1.6260.17 6.4E-02 4.88E-01
UBE3A 0.9360.05 0.8860.09 0.8160.04 0.8860.08 3.1E-01 6.50E-01
MET u.d. u.d. u.d. u.d.
NRXN1 u.d. u.d. u.d. u.d.
p-value was calculated by t test using control (n=21) and ASDs (n=21), and ctrlASD (n=21) and asdMO (n=19).
*p,0.05.
doi:10.1371/journal.pone.0024723.t005
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RPL39) were all down-regulated in both ASD and asdMO groups.
The ribosomal proteins play a crucial role in the regulation of
protein synthesis; therefore, their expression must be strictly
controlled [30]. Several lines of evidence have identified the
linkage between ribosome biogenesis and diseases such as cancer,
anemia, and aging. A recent review has also emphasized that
protein synthesis is tightly linked to the regulation of neurological
processes and cell growth [31]. The down-regulation of the genes
encoding ribosomal proteins may indirectly reflect some atypical
process of neurological development in subjects with ASD and also
mothers having children with ASD.
qPCR also validated differential expression of two genes
(MECP2 and fragile X mental retardation-1 (FMR1)), well-known
candidates for susceptibility to autism, in ASD and/or asdMO
group. The MECP2 gene encodes the X-linked methyl CpG
binding protein 2 and its mutations and dysfunctions have also
been associated with a broad array of other neurodevelopmental
disorders including autism [32]. Consistent with increased
expression of MECP2 in our study, several reports show that
overexpression of MECP2 by gene duplication is a cause of
neurodevelopmental delay in human clinical cases [33], [34].
Mutation in the MECP2 gene identical to some classical Rett
syndrome mutations has been identified in small numbers of
autistic phenotypes in females [35], [36]. Linkage analysis has
identified the over- and undertransmittance of specific MECP2
variants in families with autistic children [37]. Taken together,
these studies suggested a link between MECP2 and susceptibility to
autism. The phenotypic differences between different clinical
diagnoses may arise from differences in genetic background and
environmental exposures in each affected individual. MECP2 may
serve as a central epigenetic regulator of activity-dependent
synaptic maturation.
The mutation of FMR1 triggers abnormal methylation, resulting
in a loss of FMR1 expression in the lymphoblastoid cells in Fragile
X syndrome, and such loss of FMR1 expression was also reported
in the frontal cortex of postmortem brains from subjects with ASD
[38]. In parallel with these findings, our subjects with ASD, but
not unaffected mothers having affected children, showed signifi-
cantly decreased FMR1 mRNA levels compared with their
controls (Table 5). One might say that FMR1 may be involved
in overt manifestations of ASD.
Although the underlying mechanism of autism is considered to
be closely associated with brain maldevelopment, our results
mentioned above suggest that the dysregulated expression of
multiple candidate genes could be at least in part detectable in
peripheral leukocytes. In fact, Hu et. al. demonstrated that the
ASD-associated changes in gene expression involving in nervous
system development could be detected in lymphoblastoid cell lines
[39], [40]. Recent studies have suggested the possibility of
identifying blood biomarkers by gene expression profiling studies
in patients with mood disorders [41] and psychosis [42].
Moreover, Alter et. al. have shown autism- and increased paternal
age-related changes in global levels of gene expression regulation
in peripheral blood lymphocytes [43]. Thus, several lines of
evidence suggest that gene expression signatures for neurodevel-
opmental disorders may be detectable in peripheral blood
leukocytes. More recently, Voineagu et. al. have reported that
the expression levels of neuronal specific splicing factor A2BP1
were dysregulated in the ASD brain [19]. The splicing of A2BP1-
dependent alternative exons was also altered. However, in our
cases, A2BP1 mRNA expression was not significantly changed in
peripheral blood lymphocytes.
The implications of our approach suggest that several genes
commonly found in both affected subjects and unaffected mothers
having affected children might be potentially useful for under-
standing of mechanisms shaping the pathophysiology of ASD.
Among our validated candidates, decreased expression of FMR1
[38] and increased expression of MECP2 [33] were already
reported in lymphoblastoid cells and peripheral blood lympho-
cytes, respectively. However, the other candidate genes such as
ITGA2B, SUB1, and ribosomal protein-related genes have not
been documented. Identifying such genes could be helpful for
objective diagnosis not solely relied on overt behavioral manifes-
tations. The unique signatures observed in this study are
informative to explore the genetic, epigenetic, and environmental
background of ASD and might be a potential tool to find out the
crucial factors-related to the overthreshold and subthreshold
manifestations of ASD. To confirm these novel findings, we need
more evidence established by case-case analysis and animal- and
molecular-based studies. To show the predictive ability of the
identified marker genes, a completely independent cohort study
with larger numbers of subjects is currently underway.
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